MedTrace Logo

First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients

NCT07708116 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2026-07-16

No results posted yet for this study

Summary

The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and participants with a bacterial infection (bronchiectasis participants chronically infected with P. aeruginosa).

Conditions

Interventions

DRUG

Placebo

Placebo will be administered via IV infusion.

DRUG

CTX-187

CTX-187 will be administered via IV infusion.

Sponsors & Collaborators

  • Centauri Therapeutics Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-16
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07708116 on ClinicalTrials.gov